"Could that change over the next couple of years ? Anything is possible but EXEL has not been able to move the dial much over the past 10 years."
Tens years from IND to NDA approval is about average. Any subsequent approval will have the advantage of being a supplemental and a much larger indication. Having the optimum dose determined will work to the company's advantage in attaining those OS endpoints. Comet 2 is a shoo in for attaining its primary endpoint and I feel good about Comet 1 also.